Home › Companies › TSHA

Taysha Gene Therapies, Inc.

TSHA Rare disease Lead: Phase 3 1 Biotech Distilled article ↓

Neurology Gene Therapy

Most recent annual filing: 2026-03-19

Pipeline (3 active programs)

TSHA-102

Gene Therapy Target: MECP2

Rett Syndrome Phase 3 intrathecal

TSHA-113

Gene Therapy Target: MAPT, tau

Undisclosed indication Preclinical

TSHA-114

Gene Therapy Target: FMR1, FMRP

Fragile X Syndrome Preclinical

Discontinued (1)

TSHA-106 — Angelman Syndrome · discontinued evaluation of TSHA-106 in 2025

Biotech Distilled coverage (1)

2026-04-25 Taysha Gene Therapies (TSHA) - Scientific Deep Dive for TSHA-102 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.